-
-
-
-
-
-
-
BofA on Eli Lilly (LLY): 'Novo’s GLP-1 price update unlikely to ‘rock the boat’'
-
-
-
-
-
-
-
Novo Nordisk's CagriSema fails to match tirzepatide in obesity trial
-
-
-
-
-
-
-
Jefferies Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Hold
-
-
-
-
-
-
-
Novo Nordisk (NVO) call put ratio 1.4 calls to 1 put into share price up before the bell
-
-
-
-
-
-
-
Novo Nordisk threatens legal action over Hims & Hers semaglutide pill
-
-
-
-
-
-
-
Hims & Hers adds compounded semaglutide pills starting at $49 monthly
-
-
-
-
-
-
-
Novo Nordisk (NVO) Halted, News Pending
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

